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World Congress of DermatologyCurrently, no standardized classiﬁcation criteria exist for cutaneous lupus erythematosus. With increased
interest in studying cutaneous lupus erythematosus, speciﬁcally discoid lupus erythematosus, it is our aim
to apply previously adopted methods from rheumatology to dermatologic diseases to develop feasible,
validated, and standardized classiﬁcation criteria useful in both academic and community practice. Here we
report the progress to date to deﬁne discoid lupus erythematosus using clinical, histopathologic, and serologic
features by means of a Delphi method—using a series of iterative questionnaires sent to expert stakeholders.
We present speciﬁc updates from the World Congress of Dermatology 2015 meeting, at which a nominal
group of expert stakeholders met to discuss the results of round 1 of the Delphi process to further clarify and
harmonize speciﬁc classiﬁcation items for inclusion into round 2.
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ermatologic Society. This is an open acThe need for clinicians who specialize in connective tissue
diseases—adult and pediatric dermatologists, rheumatologists, and
dermatopathologists—to create and agree upon a classiﬁcation system
for cutaneous lupus erythematosus (CLE), speciﬁcally discoid lupus
erythematosus (DLE), was a topic of continued discussion at the
World Congress of Dermatology (WCD), which was held June 2015 in
Vancouver, Canada. At this meeting, a nominal group of stakeholders
reviewed data from round 1 of the Delphi consensus process for
designing a set of classiﬁcation criteria for DLE; the classiﬁcation
criteria item list was reviewed for harmonization, distillation, and
clariﬁcation before proceeding with round 2 of the process. Here we
review the need for uniform classiﬁcation criteria for CLE, why DLE
was chosen as the ﬁrst disease for classiﬁcation criteria design, the
results of the WCD meeting, and next steps in the process.
There is consensus—outlined previously—that CLE remains an
ill-deﬁned set of disorders that are often grouped together based on
common features, and at present, inadequate deﬁnitions of CLE
impede communication between physicians and in physician–patient
interactions (Merola et al., 2015). Furthermore, a speciﬁc classiﬁca-
tion system that allows for identiﬁcation of patients with CLE tocess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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reasons, great heterogeneity exists in studies of CLE subsets, in
particular among studies of discoid lupus cohorts, and underscores
the need for classiﬁcation criteria.
Classiﬁcation criteria, the standardized deﬁnitions that are
primarily intended to enable clinical studies to have uniform cohorts
for research, require high speciﬁcity at the expense of some sensitivity.
Classiﬁcation criteria can be applied to different geographical regions,
races, and ethnicities and do not require a gold standard test. Diagnostic
criteria, however, reﬂect a broader andmore variable set of features of a
given disease; this is less ideal for identiﬁcation of a uniform set of a
study population.
The need for a more precise classiﬁcation system for CLE was ﬁrst
formally discussed at the 3rd International Conference on Cutaneous
Lupus Erythematosus (ICCLE), held May 2013 in Edinburgh, Scotland.
The ultimate goal of this meeting was to agree on uniform deﬁnitions
and grouping schemes and the understanding of the complex
relationship between cutaneous and systemic disease. It was agreed
that the Delphi technique—a method of consensus building using a
series of iterative questionnaires to collect data from a panel of
selected experts/stakeholders—would be utilized. The point of the
Delphi technique is to achieve convergence of opinion on an issue.
Brieﬂy, experts anonymously answer questionnaires in two or more
rounds; after each round, a facilitator provides an anonymous
summary of the experts’ thoughts from the previous round. Experts
are encouraged to revise their earlier answers in light of the replies of
othermembers. During this process, the range of answers decreases as
the group converges toward one uniform answer. The beneﬁts are
subject anonymity (which reduces the effects of dominant individ-
uals) and the inclusion of a geographically inclusive cohort due to the
electronic nature of the survey. This process has been adopted
previously by rheumatologists in creating outcome measures in
rheumatoid arthritis and in developing feasible, valid, and standard-
ized classiﬁcation criteria for systemic sclerosis (Bartlett et al., 2012;
Coulter et al., 2013).
A pre–Delphi questionnaire was sent to 81 stakeholders, including
adult and pediatric dermatologists, rheumatologists, and dermato-
pathologists. The goal of the questionnaire was to query the
participants regarding the need for uniform deﬁnitions and grouping
schema for systemic lupus erythematosus and CLE and (1) to
demonstrate consensus for a new deﬁnition of CLE, (2) to better
clarify/deﬁne the relationship between CLE and systemic lupus
erythematosus, and (3) to reevaluate current disparate grouping
schema (Merola et al., 2015).
To begin the Delphi process to devise classiﬁcation schema for CLE,
it was decided that the ﬁrst focus would be on DLE, with the idea of
expanding the methodology to other subsets of CLE. DLE was
speciﬁcally selected because there is increasing interest in under-
standing DLE’s burden of disease, disease prevalence, and treatment of
recalcitrant disease. For the aims of studying DLE epidemiology and
treatment outcomes, it is important to better understand the
description of DLE for most patients and to distinguish it from disease
mimickers, such as (1) other cutaneous connective tissue disorders
(e.g., dermatomyositis, subacute cutaneous lupus) and (2) other
inﬂammatory dermatoses (e.g., tinea capitis, alopecia aerata, rosacea).
Based on discussions and breakout groups during the ICCLE
meeting in 2013, round 1 of the Delphi questionnaire, the objective
of which was to identify items for further evaluation as classiﬁcation
criteria for DLE, was created and distributed to 85 preidentiﬁedinternational experts in the ﬁeld, including adult and pediatric
rheumatologists, dermatologists, and dermatopathologists. The Del-
phi questionnaire comprised 48 items within the subcategories of
morphology, histopathology, laboratory/serology, and symptomatology;
all participants were asked to evaluate the appropriateness of the
relevance of each characteristic to the diagnosis of DLE on a numerical
scale from 0 to 100.
Sixty-one (72%) participants from Europe (31.0%), North America
(60.3%), South America (1.7%), and Asia (6.9%) completed the round 1
questionnaire. Data interpretation was performed using prespeciﬁed
cutoffs, using the median of the appropriateness ranking from 0 to
100, which effectively represents the percent consensus. It was
deemed that consensus exists for items with medians ≥70 and ≤30;
speciﬁcally, items with ≥70 were advanced to round 2, and those with
≤30 were removed from round 2 consideration. Those items with N30
but b70 were interpreted as having no consensus and technically did
not meet criteria for round 2 advancement. However, these items
were discussed among the expert panel at the WCD to ensure that
clariﬁcation was not needed in the deﬁnition before removing items
from round 2.
The initial results were presented for discussion at the WCD 2015
meeting in Vancouver. A subset of 30 participants were present, with
the overall goal of determining which items that would have been
eliminated based on statistical criteria alone should remain on the
item list while minimizing the total number of items. The participants
voted on item inclusion, provided justiﬁcation for their choices, and
were asked to provide feedback on item wording and to suggest new
items for the item list. The responses from this meeting were recorded
using an audience response system; although these responses do not
change the questionnaire items directly, the information gathered
will be used to inform the participants in the text of the round 2
questionnaire and allow the items to be voted on by a full group
of stakeholders.
Ultimately, it is the goal of the Delphi process to apply previously
adopted methods from rheumatology and other medical specialties to
dermatologic diseases in order to develop feasible, validated, and
standardized classiﬁcation criteria useful in both academic and
community practice. The classiﬁcation criteria will be supported by
further deﬁnitions and training modules to help nondermatologists
and dermatologists alike identify disease characteristics speciﬁc
for DLE.
With this goal in mind, the next steps of this process include
(1) developing a ﬁnal item list from the Delphi results to classify
DLE and (2) validating this item list using strategies similar to
those used in rheumatology to classify systemic sclerosis. Similar
strategies should be embraced for more robust classiﬁcation of other
cutaneous diseases.References
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